RGBP (Regen BioPharma) Cyclically Adjusted FCF per Share: $0.00 (As of Mar. 2026)


What is Regen BioPharma Cyclically Adjusted FCF per Share?

Regen BioPharma RGBP +100.00% Cyclically Adjusted FCF per Share is $0.00 as of Mar. 2026. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Regen BioPharma's adjusted free cash flow per share for the three months ended in Mar. 2026 was $0.000. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-06-30), Regen BioPharma's current stock price is $0.0002. Regen BioPharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $0.00. Regen BioPharma's Cyclically Adjusted Price-to-FCF of today is .


Regen BioPharma  (OTCPK:RGBP) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Regen BioPharma Cyclically Adjusted FCF per Share Related Terms


Regen BioPharma Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Regen BioPharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regen BioPharma Cyclically Adjusted FCF per Share Chart

Regen BioPharma Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -10.93 -6.15 -4.64

Regen BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.34 -4.96 -4.64 -4.20 0.00

RGBP vs SIGY, ENDV, CNBX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Regen BioPharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regen BioPharma Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's Cyclically Adjusted Price-to-FCF falls into.



Regen BioPharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Regen BioPharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0/330.2130*330.2130
=0.000

Current CPI (Mar. 2026) = 330.2130.

Regen BioPharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -2.390 241.018 -3.274
201609 -2.163 241.428 -2.958
201612 -2.639 241.432 -3.609
201703 -1.852 243.801 -2.508
201706 -2.266 244.955 -3.055
201709 -3.368 246.819 -4.506
201712 -3.283 246.524 -4.397
201803 -2.082 249.554 -2.755
201806 -0.395 251.989 -0.518
201809 -2.138 252.439 -2.797
201812 -0.549 251.233 -0.722
201903 -0.325 254.202 -0.422
201906 -0.588 256.143 -0.758
201909 -0.171 256.759 -0.220
201912 0.022 256.974 0.028
202003 -0.003 258.115 -0.004
202006 0.000 257.797 0.000
202009 0.000 260.280 0.000
202012 0.000 260.474 0.000
202103 0.000 264.877 0.000
202106 0.000 271.696 0.000
202109 0.000 274.310 0.000
202112 -0.046 278.802 -0.054
202203 -0.020 287.504 -0.023
202206 -0.019 296.311 -0.021
202209 -0.014 296.808 -0.016
202212 -0.001 296.797 -0.001
202303 -0.016 301.836 -0.018
202306 -0.013 305.109 -0.014
202309 -0.003 307.789 -0.003
202312 -0.023 306.746 -0.025
202403 -0.025 312.332 -0.026
202406 -0.021 314.175 -0.022
202409 -0.023 315.301 -0.024
202412 -0.008 315.605 -0.008
202503 -0.005 319.799 -0.005
202506 -0.002 322.561 -0.002
202509 -0.005 324.800 -0.005
202512 -0.002 324.054 -0.002
202603 0.000 330.213 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $0.00 mean?
Regen BioPharma (RGBP) has a Cyclically Adjusted FCF per Share of $0.00 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Regen BioPharma and its competitors.
Is Regen BioPharma's Cyclically Adjusted FCF per Share too high?
Regen BioPharma's current Cyclically Adjusted FCF per Share is $0.00.
How does Regen BioPharma's Cyclically Adjusted FCF per Share compare to SIGY and ENDV?
Regen BioPharma's Cyclically Adjusted FCF per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Regen BioPharma and its competitors. Regen BioPharma's current Cyclically Adjusted FCF per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current Cyclically Adjusted FCF per Share is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regen BioPharma Business Description

Other Exchanges RGBPP.PFD:USA
Address 8697 La Mesa Boulevard, Suite C, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.